LRMR · Larimar Therapeutics, Inc.
$4.10
-0.06 (-1.44%)
At close · Aug 21
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“these cash resources are not sufficient to fund the Company's planned operations for a period of at least one year from the date these unaudited condensed consolidated financial statements are issued. ... There is no assurance, however, that additional financing will be available when needed or that the Company will be able to obtain financing on terms acceptable to the Company. ... These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$441.50M
Shares
103.88M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2024-05 | — | $100,000,000 | — | — | 10-Q , filed 2026-05-14 |